New Device Shows Promise For Less-Invasive Intracranial Pressure Monitoring

A new implantable sensor device provides a less-invasive alternative for monitoring pressure within the skull (intracranial pressure, or ICP), suggests a pilot study in Operative Neurosurgery, a quarterly supplement to Neurosurgery, official journal of the Congress of Neurological Surgeons. Neurosurgery is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

"This new telemetric system was safe and effective for ICP measurement over a long period, including home monitoring," according to the study by Dr. Stefan Welschehold of University Medicine Mainz, Germany.

Initial Experience Supports Use of Telemetric ICP Monitor

The researchers evaluated the telemetric ICP monitoring system in ten patients with previous brain surgery. (Telemetry means "measurement over a distance.") The patients including children as young as three had conditions such as hydrocephalus (fluid buildup inside the skull) placing them at risk of increased ICP. Abnormally high ICP is a serious medical problem, with the potential to cause brain damage and death.

The telemetric ICP monitoring device consists of a miniature probe about one inch long attached to a disk-shaped transducer. A simple surgical procedure is performed to insert the probe tip into the brain through a small hole in the skull, and to place to transducer under the scalp.

To obtain ICP values, a recording device is simply held over the implanted sensor and transducer. Because the recording device is battery powered, the patients are completely mobile. Values can be measured even through bandages.

Eight patients continued ICP monitoring at home after being discharged from the hospital. Monitoring continued for up to six months. The main limitation was that the recording device had to be connected to a computer at least once every three weeks to clear space for data storage.

In seven out of ten patients, monitoring showed no abnormal increases in ICP and thus no need for further surgery. In these patients, the monitoring probe was eventually removed. In some cases, monitoring detected normal and temporary increases in ICP related to factors like position changes, exercise, or crying in children.

In the remaining three patients, monitoring showed persistent or recurrent increases in pressure inside the skull. This alerted doctors that further surgery was required to correct the cause of increased ICP.

Controlling ICP is a critical factor in the management of patients with hydrocephalus and certain other conditions. Current approaches to ICP monitoring have important disadvantages. The most accurate technique involves readings taken directly from a catheter inserted into the spaces within the brain. Catheter monitoring is an invasive procedure, with a significant of risk infections and other complications.

The preliminary results support the usefulness of the new system for less-invasive, fully mobile ICP monitoring. "The main advantage of this new telemetric ICP-monitoring system is the possibility of long-term measurement under daily life conditions," Dr. Welschehold and coauthors write.

Because the system is easily managed by patients and families, it may be especially valuable for ICP monitoring in children, the researchers believe. With further study including comparison with established techniques the new telemetric system could enable 24-hour monitoring, identifying patients with potentially serious increases in ICP while reducing the need for hospitalization and invasive tests.

Article adapted by Medical News Today from original press release.
Visit our neurology / neuroscience section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Wolters Kluwer Health. "New Device Shows Promise For Less-Invasive Intracranial Pressure Monitoring." Medical News Today. MediLexicon, Intl., 16 Mar. 2012. Web.
17 Mar. 2012. APA

Please note: If no author information is provided, the source is cited instead.

'New Device Shows Promise For Less-Invasive Intracranial Pressure Monitoring'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Read More »

14.14 | 0 komentar

Combination Treatment In Mice Shows Promise For Fatal Neurological Disorder In Kids

Infants with Batten disease, a rare but fatal neurological disorder, appear healthy at birth. But within a few short years, the illness takes a heavy toll, leaving children blind, speechless and paralyzed. Most die by age 5.
There are no effective treatments for the disease, which can also strike older children. And several therapeutic approaches, evaluated in mouse models and in young children, have produced disappointing results.
But now, working in mice with the infantile form of Batten disease, scientists at Washington University School of Medicine in St. Louis and Kings College London have discovered dramatic improvements in life span and motor function by treating the animals with gene therapy and bone marrow transplants.
The results are surprising, the researchers say, because the combination therapy is far more effective than either treatment alone. Gene therapy was moderately effective in the mice, and bone marrow transplants provided no benefit, but together the two treatments created a striking synergy.
The research is reported online in the Annals of Neurology.
"Until now, this disease has been refractory to every therapy that has been thrown at it," says senior author Mark Sands, PhD, professor of medicine and of genetics at the School of Medicine. "The results are the most hopeful to date, and they open up a new avenue of research to find effective therapies to fight this devastating disease."
The combination therapy did not cure the disease, the scientists caution, but mice that received both treatments experienced significant, lasting benefits.
Mice that got gene therapy and a bone marrow transplant lived nearly 18.5 months, more than double the lifespan of untreated mice with the disease. (Healthy laboratory mice live about 24 months.) And for a significant portion of their lives, motor skills in mice that got both therapies were indistinguishable from those in normal, healthy mice.
While bone marrow transplants carry significant risks, especially in children, the researchers say they may be able to combine gene therapy with another treatment to achieve the same results. This same approach potentially could be used to treat other forms of Batten disease.
Batten disease is an inherited genetic disorder that strikes fewer than five of every 100,000 U.S. children but is slightly more common in northern Europe. There are several forms of the disease, diagnosed at different ages, and all are related to the inability of cells to break down and recycle proteins.
The infantile form is caused by mutations in the PPT1 gene that codes for an enzyme needed to remove these proteins from cells. Without a working copy of the gene, the proteins build up in cells, causing seizures, brain atrophy and dementia. The disease progresses most rapidly when it is diagnosed in infants. By age 2, most live in an unresponsive, vegetative state.
In the new study, the researchers tested various therapies in four groups of newborn mice with infantile Batten disease. One received only gene therapy; another received only bone marrow transplants; a third was treated with gene therapy and bone marrow transplants; and a fourth group received no treatment. As a comparison, the study included healthy mice without the disorder.
Gene therapy to replace the PPT1 enzyme was delivered directly into the brain. Bone marrow transplants were given with the intent that donor cells would migrate to the brain and deliver additional enzyme to regions of the brain not reached by gene therapy.
But that's not what happened, Sands says. Although gene therapy delivered relatively high levels of PPT1 enzyme, the bone marrow transplants did not supply any additional enzyme. Rather, he and his colleagues discovered that mice receiving both therapies experienced a dramatic reduction in brain inflammation.
"We suspect that the normal immune cells from the bone marrow transplant substantially reduce inflammation in the brain because we just don't see much of it in mice that got both therapies," Sands says. "This helps the PPT1 enzyme to do its job inside cells."
The study's results show no increase in life span for mice receiving bone marrow transplantation alone compared to untreated mice animals in both groups lived a median of 8.9 months. Mice that got only gene therapy lived 13.5 months, while those that got the combination therapy lived for 18.5 months.
The researchers noted similar effects of the therapies when they evaluated motor function. By 6 months, both untreated mice and those that received only a bone marrow transplant had experienced significant declines in motor skills. Mice that got gene therapy alone experienced a decline in motor function beginning at 10 months, and in those that got combination therapy, motor skills did not begin to decline until 13 months and did so more gradually than in the other mice.
Mice that got the combination therapy also had higher levels of active PPT1 enzyme in the brain, a thicker cerebral cortex and fewer accumulated proteins in brain cells, all indicators that the treatment is working.
Sands is now repeating the experiment and investigating other ways to reduce inflammation in the brain that would not involve the risks of a bone marrow transplant. One possibility, he says, involves anti-inflammatory drugs that have effects in the brain.
"We may be able to achieve the same results with a less invasive anti-inflammatory treatment," Sands says. "We're very excited now to move forward."
The research is supported by the National Institutes of Health (NIH), Ruth L. Kirschstein NRSA Fellowship, The Wellcome Trust, Batten Disease Family Association, the Batten Disease Support and Research Association and the Bletsoe Family.
Macauley SL, Roberts MS, Wong AM, McSloy F, Reddy AS, Cooper JD and Sands MS. Synergisitc effects of CNS-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Annals of Neurology. Online ahead of print, Feb. 24, 2012.
Article adapted by Medical News Today from original press release.
Visit our pediatrics / children's health section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:
MLA

Washington University in St. Louis. "Combination Treatment In Mice Shows Promise For Fatal Neurological Disorder In Kids." Medical News Today. MediLexicon, Intl., 16 Mar. 2012. Web.
17 Mar. 2012. APA

Please note: If no author information is provided, the source is cited instead.

'Combination Treatment In Mice Shows Promise For Fatal Neurological Disorder In Kids' Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Read More »

12.00 | 0 komentar